In short
Lanifibranor is an innovative drug currently being studied in clinical trials for its potential to treat various metabolic disorders, including nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. This article explores the ongoing research into Lanifibranor's safety, efficacy, and pharmacokinetics across different patient populations and dosing regimens.
At a glance
- Drug Name
- Lanifibranor (also known as IVA337)
- Drug Class
- Pan-peroxisome proliferator-activated receptor (PPAR) agonist
- Conditions Studied
- Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
- Dosages
- 800 mg/day, 1200 mg/day (varies by study)
- Study Designs
- Randomized, double-blind, placebo-controlled trials
- Primary Outcomes
- Changes in intrahepatic triglycerides, pharmacokinetic parameters, safety assessments
- Secondary Outcomes
- Liver fibrosis markers, insulin sensitivity, lipid profiles, glycemic control
- Study Populations
- Healthy volunteers, patients with T2DM and NAFLD, Chinese subjects
- Key Measurements
- MRI/MRS imaging, blood tests, euglycemic hyperinsulinemic clamp, liver stiffness assessments
What is Lanifibranor?
Lanifibranor, also known as IVA337, is a new drug being developed to treat various liver and metabolic disorders. It is currently undergoing clinical trials to evaluate its effectiveness and safety in patients with specific conditions.
How Does Lanifibranor Work?
Lanifibranor is classified as a pan-peroxisome proliferator-activated receptor (PPAR) agonist. This means it activates certain proteins in the body called PPARs, which play important roles in regulating metabolism, inflammation, and cell growth. By targeting these receptors, Lanifibranor aims to improve various aspects of liver and metabolic health.
What Conditions Does Lanifibranor Treat?
Based on the ongoing clinical trials, Lanifibranor is being studied for the treatment of the following conditions:
- Nonalcoholic Fatty Liver Disease (NAFLD): A condition where excess fat accumulates in the liver of people who drink little or no alcohol.
- Type 2 Diabetes (T2DM): A chronic condition that affects the way your body processes blood sugar (glucose).
Researchers are particularly interested in how Lanifibranor might help patients who have both NAFLD and type 2 diabetes, as these conditions often occur together and can worsen each other.
Current Clinical Trials
Several clinical trials are currently underway to evaluate Lanifibranor:
- Pharmacokinetic Study in Chinese Subjects: This study aims to understand how Lanifibranor is processed in the bodies of healthy Chinese adults.
- Efficacy in Patients with Type 2 Diabetes and NAFLD: This trial is investigating how well Lanifibranor works in reducing liver fat and improving various metabolic parameters in patients with both conditions.
- Safety and Dosing Study: This study is evaluating the safety and appropriate dosing of Lanifibranor in healthy volunteers.
Dosage and Administration
The dosage of Lanifibranor is still being determined through clinical trials. Current studies are testing doses ranging from 800 mg to 1200 mg per day, taken orally. It's important to note that the optimal dose may vary depending on the condition being treated and individual patient factors.
Safety and Side Effects
As Lanifibranor is still in the clinical trial phase, its full safety profile is not yet established. Researchers are closely monitoring for any adverse events, which may include:
- Changes in vital signs (blood pressure, pulse)
- Abnormalities in clinical laboratory tests (blood and urine tests)
- Changes in electrocardiogram (ECG) parameters (heart rhythm measurements)
- Any other unexpected side effects
It's important to remember that Lanifibranor is not yet approved for general use, and its safety and effectiveness are still being evaluated. Patients interested in this treatment should discuss potential clinical trial participation with their healthcare providers.